Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab

Leukemia. 2021 Mar;35(3):929-931. doi: 10.1038/s41375-021-01167-8. Epub 2021 Feb 17.

Authors

Shuntaro Ikegawa¹, Yusuke Meguri¹, Kentaro Mizuhara¹, Takuya Fukumi¹, Hiroki Kobayashi¹, Yuichi Sumii¹, Takumi Kondo¹, Yasuhisa Sando¹, Miki Iwamoto¹, Noboru Asada¹, Daisuke Ennishi¹, Hisakazu Nishimori¹, Keiko Fujii¹, Nobuharu Fujii¹, Yuka Fujisawa², Toshi Imai², Yoshinobu Maeda¹, Ken-Ichi Matsuoka³

Affiliations

¹ Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
² Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
³ Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. k-matsu@md.okayama-u.ac.jp.

PMID: 33597730
DOI: 10.1038/s41375-021-01167-8

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cyclophosphamide / adverse effects
Hematopoietic Stem Cell Transplantation*
Immune Tolerance
Nivolumab* / adverse effects
T-Lymphocytes, Regulatory

Substances

Nivolumab
Cyclophosphamide